The development, characterization and in vivo anti-ovarian cancer activity of poly(propylene imine) (PPI)-antibody conjugates containing encapsulated paclitaxel

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 11, Issue 1, 2015, Pages 207-218

  Jain, Narendra K ^a   Tare, Manoj S ^a   Mishra, Vijay ^a   Tripathi, Pushpendra K ^b  

^a DR H S GOUR UNIVERSITY   (India)

^b Department of Pharmacy RITM   (India)

Author keywords

Cytotoxicity; Immunodendrimers; Ovarian cancer; Poly(propylene imine) dendrimer; Tumor growth inhibition

Indexed keywords

ANTIBODIES; CYTOTOXICITY; DENDRIMERS; FLOW CYTOMETRY; FUNCTIONAL POLYMERS; NITROGEN COMPOUNDS; PROPYLENE; TUMORS;

BIOLOGICAL FUNCTIONS; IMMUNODENDRIMERS; OVARIAN CANCER CELLS; OVARIAN CANCERS; POLY (PROPYLENE IMINE) DENDRIMERS; POLY(PROPYLENE IMINE); THERAPEUTIC OUTCOMES; TUMOR GROWTH;

DISEASES;

DENDRIMER; MESOTHELIN; PACLITAXEL; POLY(PROPYLENE IMINE); UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; LACTATE DEHYDROGENASE; POLY(PROPYLENEIMINE); POLYPROPYLENE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL STRUCTURE; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG RELEASE; DRUG SYNTHESIS; DRUG TARGETING; ELIMINATION RATE CONSTANT; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VIVO STUDY; INFRARED SPECTROSCOPY; MOUSE; NONHUMAN; OVARY CANCER; PROTEIN EXPRESSION; PROTON NUCLEAR MAGNETIC RESONANCE; TRANSMISSION ELECTRON MICROSCOPY; TUMOR VOLUME; ANIMAL; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; CHEMISTRY; DRUG DELIVERY SYSTEM; NANOMEDICINE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OVARIAN NEOPLASMS; PROCEDURES; SURFACE PROPERTY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DENDRIMERS; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; L-LACTATE DEHYDROGENASE; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MICE, INBRED BALB C; MICROSCOPY, ELECTRON, TRANSMISSION; NANOMEDICINE; NEOPLASM TRANSPLANTATION; OVARIAN NEOPLASMS; PACLITAXEL; POLYPROPYLENES; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; SURFACE PROPERTIES;

EID: 84919668203     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2014.09.006     Document Type: Article

References (51)

1. Cancer Research UK [Accessed date 20th January 2014]. http://www.cancerresearchuk.org/cancer-info/cancerstats/keyfacts/ovarian-cancer/.
2. Jelovac D., Armstrong D.K. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin 2011, 61:183-203.
3. World Cancer Research Fund International [Accessed date 20th January 2014]. http://www.wcrf.org/cancer_statistics/world_cancer_statistics.php.
4. Kesharwani P., Jain K., Jain N.K. Dendrimer as nanocarrier for drug delivery. Prog Polym Sci 2014, 39:268-307.
5. Jain N.K., Mishra V., Mehra N.K. Targeted drug delivery to macrophages. Expert Opin Drug Deliv 2013, 10:353-367.
6. Mishra V., Gupta U., Jain N.K. Surface-engineered dendrimers: a solution for toxicity issues. J Biomater Sci 2009, 20:141-166.
7. Mishra V., Jain N.K. Acetazolamide encapsulated dendritic nano-architectures for effective glaucoma management in rabbits. Int J Pharm 2014, 461:380-390.
8. Tekade R.K., Kumar P.V., Jain N.K. Dendrimers in oncology: an expanding horizon. Chem Rev 2009, 109:49-87.
9. Boas U., Hegard P.M.H. Dendrimers in drug research. Chem Soc Rev 2004, 33:43-63.
10. Bergamini G., Marchi E., Ceroni P., Balzani V. Enlightening structure and properties of dendrimers by fluorescence depolarization. Designing Dendrimers 2012, 341-366. Wiley, Hoboken, USA. S. Campagna, P. Ceroni, F. Puntoriero (Eds.).
11. Tomalia D.A., Christensen J.B., Boas U. Dendrimers, dendrons and dendritic polymers: discovery, applications, the future 2012, 1-344. Cambridge University Press, New York, USA.
12. Teow H.M., Zhou Z., Najlah M., Yusof S.R., Abbott N.J., D'Emanuele A. Delivery of paclitaxel across cellular barriers using a dendrimer-based nanocarrier. Int J Pharm 2013, 441:701-711.
13. Saovapakhiran A., D'Emanuele A., Attwood D., Penny J. Surface modification of PAMAM dendrimers modulates the mechanism of cellular internalization. Bioconjug Chem 2009, 20:693-701.
14. Najlah M., D'Emanuele A. Crossing cellular barriers using dendrimer nanotechnologies. Curr Opin Pharmacol 2006, 6:522-527.
15. D'Emanuele A., Attwood D. Dendrimer-drug interactions. Adv Drug Deliv Rev 2005, 57:2147-2162.
16. Lambert J.M. Drug-conjugated monoclonal antibodies for treatment of cancer. Curr Opin Pharmacol 2005, 5:543-549.
17. Mehra N.K., Mishra V., Jain N.K. Receptor-based targeting of therapeutics. Ther Deliv 2013, 4:369-394.
18. Garg G., Gibbs J., Belt B., Powell M.A., Mutch D.G., Goedegebuure P., et al. Novel treatment option for MUC16-positive malignancies with the targeted TRAIL-based fusion protein Meso-TR3. BMC Cancer 2014, 14:35-47.
19. Cheng W.F., Huang C.Y., Chang M.C., Hu Y.H., Chiang Y.C., Chen Y.L., et al. High mesothelin correlates with chemoresistance and poor survival in epithelial ovarian carcinoma. Br J Cancer 2009, 100:1144-1153.
20. Hassan R., Bera T., Pastan I. Mesothelin: a new target for immunotherapy. Clin Cancer Res 2004, 10:3937-3942.
21. Mishra V., Gupta U., Jain N.K. Influence of different generations of poly(propylene imine) dendrimers on human erythrocytes. Pharmazie 2010, 65:891-895.
22. Rietvlad I.B., Bouwman W.G., Baars M.W.P.L., Heenan R.K. Location of the outer shell and influence of pH on carboxylic acid functionalized poly(propylene imine) dendrimers. Macromolecules 2001, 34:8380-8383.
23. Carter J.M. Conjugation of peptides to carrier protein via carbodiimide. The Protein Protocols Handbook 1996, 286. Humana Press Inc., Totowa, NJ. M.J. Walker (Ed.).
24. Illoh O.C. Current applications of flow cytometry in the diagnosis of primary immunodeficiency diseases. Arch Pathol Lab Med 2004, 128:23-31.
25. Bradford M.M. Rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254.
26. Noble J.E., Bailey M.J.A. Quantitation of protein. Methods Enzymol 2009, 463:73-95.
27. Gajbhiye V., Vijayaraj Kumar P., Tekade R.K., Jain N.K. PEGylated PPI dendritic architectures for sustained delivery of H2 receptor antagonist. Eur J Med Chem 2009, 44:1155-1166.
28. Gajbhiye V., Jain N.K. The treatment of glioblastoma xenografts by surfactant conjugated dendritic nanoconjugates. Biomaterials 2011, 32:6213-6225.
29. Lee S.H., Yoo S.D., Lee K.H. Rapid and sensitive determination of paclitaxel in mouse plasma by high performance liquid chromatography. J Chromatogr B Biomed Sci Appl 1999, 724:357-363.
30. Tekade R.K., Dutta T., Gajbhiye V., Jain N.K. Exploring dendrimer towards dual drug delivery: pH responsive simultaneous drug release kinetics. J Microencapsul 2009, 26:287-296.
31. Gubbels J.A.A., Belisle J., Onda M., Rancourt C., Migneault M., Ho M., et al. Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer 2006, 5:50-58.
32. Hassan R., Kreitman R.J., Pastan I., Willingham M.C. Localization of mesothelin in epithelial ovarian cancer. Appl Immunohistochem Mol Morphol 2005, 13:243-247.
33. Chang C.L., Wu T.C., Hung C.F. Control of human mesothelin expressing tumors by DNA vaccines. Gene Ther 2007, 14:1189-1198.
34. Decker T., Lohmann-Mathes M.L. A quick and simple method for quantitation of LDH release in measurements of cellular cytotoxicity and tumor necrosis factor activity. J Immunol Methods 1988, 115:61-69.
35. Fischer D., Li Y., Ahlemeyer B., Krieglstein J., Kissel T. In vitro cytotoxicity of polymer structure on cell viability and haemolysis. Biomaterials 2003, 24:1121-1131.
36. Shukla R., Thomas T.P., Peters J.L., Desai A.M., Kukowska-Latallo J., Patri A.K., et al. HER2 specific tumor targeting with dendrimer conjugated anti-HER2 mAb. Bioconjug Chem 2006, 17:1109-1115.
37. Badea I., Cituaru D., Lazar L., Nicolescu D., Tudose A. Rapid HPLC method for the determination of paclitaxel in pharmaceutical formulations without separation. J Pharm Biomed Anal 2004, 34:501-507.
38. Singh P., Gupta U., Asthana A., Jain N.K. Folate and Folate-PEG-PAMAM dendrimers: synthesis, characterization and targeted anticancer drug delivery potential in tumor bearing mice. Bioconjug Chem 2008, 19:2239-2252.
39. Dhanikula A.B., Singh D.R., Panchagnula R. In vivo pharmacokinetic and tissue distribution studies in mice of alternative formulations for local and systemic delivery of paclitaxel: gel film, prodrug, liposomes and micelles. Curr Drug Deliv 2005, 2:35-44.
40. Tuffery A.A. Laboratory animals an introduction for new experimenters 1987, 287-290. Wiley, New York, USA.
41. Trasler J., Deng L., Melnyk S., Pogribny I., Hiou-Tim F., Sibani S., et al. Impact of Dnmt1 deficiency, with and without low folate diets, on tumor numbers and DNA methylation in Min mice. Carcinogenesis 2003, 24:39-45.
42. Pastorino F., Di Paolo D., Piccardi F. Enhanced antitumor efficacy of clinical-grade vasculature-targeted liposomal doxorubicin. Clin Cancer Res 2008, 4:7320-7327.
43. Bookman M.A., McGuire W.P., Kilpatrick D., Keenan E., Hogan W.M., Johnson S.W., et al. Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group. J Clin Oncol 1996, 14:1895-1902.
44. Willey T.A., Bekos E.J., Gaver R.C., Duncan G.F., Tay L.K., Beijnen J.H., et al. High-performance liquid chromatographic procedure for the quantitative determination of paclitaxel (Taxol) in human plasma. J Chromatogr 1993, 621:231-238.
45. De Brabender Van Den Berg E.M.M., Meijer E.W. Poly(propylene)imine dendrimers. Large scale synthesis by heterogeneously catalyzed hydrogenation. Angew Chem Int Ed 1993, 32:1308-1311.
46. Ooya T., Lee J., Park K. Hydrotropic dendrimers of generations 4 and 5: synthesis, characterization and hydrotropic solubilization of paclitaxel. Bioconjug Chem 2004, 15:1221-1229.
47. Jevprasesphant R., Penny J., Jalal R., Attwood D., McKeown N.B., D'Emanuele A. The influence of surface modification on the cytotoxicity of PAMAM dendrimers. Int J Pharm 2003, 252:263-266.
48. Bhadra D., Yadav A.K., Bhadra S., Jain N.K. Glycodendrimeric nanoparticulate carriers of primaquine phosphate for liver targeting. Int J Pharm 2005, 295:221-233.
49. Agashe H.B., Dutta T., Garg M., Jain N.K. Investigations on the toxicological profile of functionalized fifth generation poly(propyleneimine) dendrimer. J Pharm Pharmacol 2006, 58:1491-1498.
50. Agrawal P., Gupta U., Jain N.K. Glycoconjugated peptide dendrimers based nanoparticulate system for the delivery of chloroquine phosphate. Biomaterials 2007, 28:3349-3359.
51. Malik N., Wiwattanapatapee R., Klopsch R., Lorenz K., Frey H., Weener J.W., et al. Dendrimers: relationship between structure and biocompatibility in vitro and preliminary studies on biodistribution of 125I labeled polyamido amine dendrimers in vivo. J Control Release 2000, 65:133-148.